A ten-week therapeutic trial with T.P.S.-23 (mesoridazine) was carried out on twelve cases of chronic childhood psychosis. Results showed an improvement in behaviour; the target symptoms most responsible for the differences in scores were anxiety, tension, emotional withdrawal and blunted affect. The clinical picture clearly deteriorated during the two-week period on placebo. There were no major untoward effects other than a case of acute hypotension in one patient, who had to be withdrawn from the trial (an 18-year old boy receiving the fixed maximum dose: 400 mg./day) and a case of preclinical, cellular type liver toxicity, whose origin cannot with certitude be attributed to mesoridazine.
References
1.
BaldwinR., KennyT., et BadieD.: A new drug for behaviour problems in children: a preliminary report.Current Therapeutic Research, Vol. 9, No. 9: 457–461, 1967.
2.
DouglasK.: Some effects of mesoridazine (T.P.S.-23) on chronic psychiatric patients.Diseases of Nervous System, Vol. 28: 113–117, 1967.
3.
GallantD. M., et BishopM. P.: Transient granulocytopenia associated with administration of a new thioridazine derivative: T.P.S.-23.Amer. J. Psych., Vol. 155: 102–103, 1965.
4.
GoldsteinB., et DippyW.: A clinical evaluation of mesoridazine (Serentil) in geriatric patients.Current Therapeutic Research, Vol. 9, No. 5: 256–260, 1967.
5.
LowestamI.: The effects of mesoridazine, a new thioridazine derivative, in alcoholics.Journal of Clinical Pharmacology, Vol. 7, No. 2: 111–115, 1967.
6.
Medical Department, Sandoz Pharmaceuticals: T.P.S.-23.Clinical Investigation Brochure.Hanover, N.J., U.S.A., March 1965.
7.
PrusmackJ.: Mesoridazine (T.P.S.-23), a new antipsychotic drug.The Journal of New Drugs, Vol. 6, No. 3: 182–188, 1966.
8.
SugermanA.: Comparison of T.P.S.-23 and thioridazine in chronic schizophrenic patients.Current Therapeutic Research, Vol. 7, No. 9: 520–527, 1965.
